Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease.

Scorletti E, Byrne CD.

Annu Rev Nutr. 2013;33:231-48. doi: 10.1146/annurev-nutr-071812-161230. Review.

PMID:
23862644
2.

Dietary supplementation of herring roe and milt enhances hepatic fatty acid catabolism in female mice transgenic for hTNFα.

Bjørndal B, Burri L, Wergedahl H, Svardal A, Bohov P, Berge RK.

Eur J Nutr. 2012 Sep;51(6):741-53. doi: 10.1007/s00394-011-0254-8. Epub 2011 Oct 11.

PMID:
21986673
3.

Omega 3 - Omega 6: What is right for the liver?

El-Badry AM, Graf R, Clavien PA.

J Hepatol. 2007 Nov;47(5):718-25. Epub 2007 Sep 14. Review.

PMID:
17869370
4.

A lipidomic analysis of nonalcoholic fatty liver disease.

Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ.

Hepatology. 2007 Oct;46(4):1081-90.

PMID:
17654743
5.

Fatty liver: role of inflammation and fatty acid nutrition.

Byrne CD.

Prostaglandins Leukot Essent Fatty Acids. 2010 Apr-Jun;82(4-6):265-71. doi: 10.1016/j.plefa.2010.02.012. Epub 2010 Mar 2. Review.

PMID:
20189787
6.

Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids.

Bouzianas DG, Bouziana SD, Hatzitolios AI.

Nutr Rev. 2013 Nov;71(11):753-71. doi: 10.1111/nure.12073. Epub 2013 Oct 22. Review.

PMID:
24148001
7.

[A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis].

Nakamoto K, Obata T, Hirasawa A, Kim KI, Kim SR, Tokuyama S.

Yakugaku Zasshi. 2016;136(4):583-9. doi: 10.1248/yakushi.15-00264-4. Review. Japanese.

8.

Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis.

Lazic M, Inzaugarat ME, Povero D, Zhao IC, Chen M, Nalbandian M, Miller YI, Cherñavsky AC, Feldstein AE, Sears DD.

PLoS One. 2014 Sep 24;9(9):e107658. doi: 10.1371/journal.pone.0107658. eCollection 2014.

9.

Effect of diet and omega-3 fatty acids in NAFLD.

Popescu LA, Vîrgolici B, Lixandru D, Miricescu D, Condruţ E, Timnea O, Ranetti AE, Militaru M, Mohora M, Zăgrean L.

Rom J Morphol Embryol. 2013;54(3 Suppl):785-90.

10.

Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis.

López-Vicario C, González-Périz A, Rius B, Morán-Salvador E, García-Alonso V, Lozano JJ, Bataller R, Cofán M, Kang JX, Arroyo V, Clària J, Titos E.

Gut. 2014 Feb;63(2):344-55. doi: 10.1136/gutjnl-2012-303179. Epub 2013 Mar 14.

PMID:
23492103
11.

Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis.

Savard C, Tartaglione EV, Kuver R, Haigh WG, Farrell GC, Subramanian S, Chait A, Yeh MM, Quinn LS, Ioannou GN.

Hepatology. 2013 Jan;57(1):81-92. doi: 10.1002/hep.25789.

12.

A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury.

Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, De Minicis S, Nobili L, Salzano R, Omenetti A, Pacetti D, Sigmund S, Benedetti A, Casini A.

Am J Pathol. 2006 Sep;169(3):846-60.

13.

Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model.

Enos RT, Velázquez KT, McClellan JL, Cranford TL, Walla MD, Murphy EA.

Nutr Res. 2015 May;35(5):449-59. doi: 10.1016/j.nutres.2015.04.003. Epub 2015 Apr 11.

14.

Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice.

Tajima K, Nakamura A, Shirakawa J, Togashi Y, Orime K, Sato K, Inoue H, Kaji M, Sakamoto E, Ito Y, Aoki K, Nagashima Y, Atsumi T, Terauchi Y.

Am J Physiol Endocrinol Metab. 2013 Oct 15;305(8):E987-98. doi: 10.1152/ajpendo.00133.2013. Epub 2013 Aug 20.

15.

[Activation of Kupffer cell and related signal pathway proteins in the liver of high fat and high fructose diet induced NAFLD mice].

Zhu ML, Liu J, Liu YL, Yang WJ, Luo Y, Zhuang ZJ, Jiao QB, Chen JY, Yan J, Bian DX, Ma XJ, Xun YH, Shi JP.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2013 Oct;27(5):325-7. Chinese.

PMID:
24645313
16.

Estimation of fish and ω-3 fatty acid intake in pediatric nonalcoholic fatty liver disease.

St-Jules DE, Watters CA, Brunt EM, Wilkens LR, Novotny R, Belt P, Lavine JE; Nonalcoholic Steatohepatitis Clinical Research Network..

J Pediatr Gastroenterol Nutr. 2013 Nov;57(5):627-33. doi: 10.1097/MPG.0b013e3182a1df77.

17.

Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.

Jump DB, Depner CM, Tripathy S, Lytle KA.

Adv Nutr. 2015 Nov 13;6(6):694-702. doi: 10.3945/an.115.009423. Print 2015 Nov. Review.

18.

Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins.

González-Périz A, Horrillo R, Ferré N, Gronert K, Dong B, Morán-Salvador E, Titos E, Martínez-Clemente M, López-Parra M, Arroyo V, Clària J.

FASEB J. 2009 Jun;23(6):1946-57. doi: 10.1096/fj.08-125674. Epub 2009 Feb 11.

20.

Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.

Musso G, Cassader M, De Michieli F, Rosina F, Orlandi F, Gambino R.

Hepatology. 2012 Sep;56(3):933-42. doi: 10.1002/hep.25739. Epub 2012 Jul 3.

PMID:
22684858

Supplemental Content

Support Center